<DOC>
	<DOCNO>NCT01809262</DOCNO>
	<brief_summary>Primary objective : To investigate bronchodilator effect safety single dos BI 1744 CL inhale via Respimat inhaler , Secondary objective : characterize pharmacokinetics BI 1744 CL . Olodaterol dose 40 mcg investigate open-label extension part additional PK assessment define primary secondary endpoint .</brief_summary>
	<brief_title>Single Dose Ranging Study BI 1744 CL ( Olodaterol ) Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olodaterol</mesh_term>
	<criteria>Inclusion criterion : 1 . Diagnosis chronic obstructive pulmonary disease 2 . Smoking history 10pack year Exclusion criterion : 1 . History asthma , allergic rhinitis , myocardial infarction unstable lifethreatening cardiac arrhythmia 2 . Marked baseline prolongation QT/QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>